EUVIMEDEUVIMED entdecken
Crossref

Reduction-Responsive Docetaxel Prodrug Encapsulated within Human Serum Albumin Nanoparticles for Cancer Therapy

Yanhao Zhang, Hao Zhang, Ji Wang, Chao Liu, Hanlei Xing, Yuhao Jiang, Xinsong Li iD

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.2c01107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Yanhao Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, P. R. China. Hauptthemen laut MEDLINE: Prodrugs, Nanoparticles, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Jiangsu Provincial Key Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Docetaxel (DTX), a semisynthetic analogue of paclitaxel, is often used to treat cancers. Owing to its poor aqueous solubility, the current formulation of DTX for clinical applications involves using high surfactant and ethanol concentrations, causing hypersensitivity reactions. To overcome this issue, we developed a reduction-responsive DTX prodrug encapsulated within human serum albumin (HSA) nanoparticles (DTX-SS-COOH/HSA NPs). First, the DTX prodrug was conjugated to undecanoic acid through a disulfide bond (DTX-SS-COOH) via a four-step reaction. Subsequently, DTX-SS-COOH/HSA NPs were prepared via the desolvation method. The NPs exhibited a spherical structure with a diameter range of 140-220 nm, as revealed by dynamic light scattering and transmission electron microscopy. Fluorescence quenching analysis confirmed the formation of DTX-SS-COOH/HSA, which was ascribed to electrostatic interactions and hydrophobic forces. Notably, NPs with a feed mole ratio corresponding to DTX-SS-COOH/HSA = 9:1 demonstrated high drug-loading and encapsulation efficiency of 12.84 and 93.11%, respectively, alongside good stability. Moreover, the reduced responsiveness experiment revealed an accelerated DTX release in the presence of glutathione. An in vivo pharmacokinetic study indicated that DTX-SS-COOH/HSA NPs demonstrated considerably a prolonged circulation time (6.2-fold) compared to that of free DTX. Ultimately, the antitumor test of MDA-MB-231 tumor-bearing mice revealed that DTX-SS-COOH/HSA NPs were superior to DTX/HSA NPs for tumor growth inhibition. Thus, DTX-SS-COOH/HSA NPs represent a promising DTX nanoformulation for clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsNanoparticlesAntineoplastic AgentsNeoplasmsHumansMiceAnimalsDocetaxelSerum Albumin, HumanPaclitaxelDrug CarriersCell Line, Tumor

Stichwörter der Autor:innen

docetaxelhuman serum albuminnanoparticlesprodrugreduced responsiveness

Substanzen

DocetaxelProdrugsSerum Albumin, HumanPaclitaxelDrug CarriersAntineoplastic Agents

Autor:innen und Institutionen

  • School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, P. R. China.

ORCID-Profile: Xinsong Li

Förderung

  • Jiangsu Provincial Key Research and Development Program

Zitieren

APA

Zhang, Y., Zhang, H., Wang, J., Liu, C., Xing, H., Jiang, Y., & Li, X. (2023). Reduction-Responsive Docetaxel Prodrug Encapsulated within Human Serum Albumin Nanoparticles for Cancer Therapy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.2c01107

Vancouver

Zhang Y, Zhang H, Wang J, Liu C, Xing H, Jiang Y, et al. Reduction-Responsive Docetaxel Prodrug Encapsulated within Human Serum Albumin Nanoparticles for Cancer Therapy. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.2c01107

BibTeX
@article{Zhang2023,
  author = {Zhang, Yanhao and Zhang, Hao and Wang, Ji and Liu, Chao and Xing, Hanlei and Jiang, Yuhao and Li, Xinsong},
  title = {Reduction-Responsive Docetaxel Prodrug Encapsulated within Human Serum Albumin Nanoparticles for Cancer Therapy},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.2c01107}
}
Kostenlos starten →